Drug List


Drug Name

Bexxar (Tositumomab and iodine)

Manufactured By

GlaxoSmithKline LLC

Drug Savings

NPC's mission is your health. We recognize your need for help when you are applying for discount programs for your prescription medications. We consist of friendly and experienced advocates that not only know how these free and discount programs work, but are ready to help. We are available to take your call and answer any questions you may have as you search for the right program to fit your needs. We can also explain any supporting material you may need to provide as you apply for these programs. If for any reason you are denied, we also are experienced in the best appeals process with a high success rate.

Nationwide Prescription Connection (NPC) is an experienced advocacy service that helps connect patients to manufacturer provided free and discount programs. We can help the uninsured, under insured, those in the Medicare gap also known as the "doughnut hole", or even those needing help with expensive co-pays.  Our web site makes it easy for you to enter the medications you are taking, along with some basic patient information, and then finds the program that is right for you.

Treats Disease/Condition


The BEXXAR® therapeutic regimen (tositumomab and iodine I 131 tositumomab) is indicated for the treatment of patients with CD20-positive relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma.

How To Use

The BEXXAR therapeutic regimen consists of 2 separate components (tositumomab and iodine I 131 tositumomab) administered in 2 separate steps (dosimetric dose and therapeutic dose) separated by 7 to 14 days.

Side Effects

Some people receiving a tositumomab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, sweaty, or short of breath, or if you have fever or chills during the injection. Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. The most common adverse reactions in patients receiving the BEXXAR therapeutic regimen (per-patient incidence greater than 25%) were neutropenia, thrombocytopenia, anemia, infections (including pneumonia, bacteremia, septicemia, bronchitis, and skin infections), infusion reactions, asthenia, fever, and nausea [see BOXED WARNING, WARNINGS AND PRECAUTIONS]. The most common serious adverse reactions in patients receiving the BEXXAR therapeutic regimen were severe and prolonged cytopenias, infections (including pneumonia, bacteremia, septicemia, bronchitis, and skin infections), serious allergic reactions (including bronchospasm and angioedema), infusion reactions, and secondary leukemia and myelodysplastic syndrome

Drug Interactions

No formal drug-drug interaction studies have been conducted with tositumomab or I-131 tositumomab.

In Case of Overdose

The maximum radiation activity of the I-131 component of the BEXXAR therapeutic regimen, administered to 4 patients, were doses calculated to deliver between 85 cGy and 88 cGy total body irradiation. The incidence of NCI Grade 4 cytopenias was increased in these 4 patients compared to patients who received the recommended therapeutic dose for the BEXXAR therapeutic regimen.

In Case of Missed Dose